Printer Friendly

ALAMAR BIOSCIENCES SECURES FDA CLEARANCE FOR READING INSTRUMENT; MOVES CLOSER TO COMPLETING PRODUCT LINE

 SACRAMENTO, Calif., Sept. 14 /PRNewswire/ -- Alamar Biosciences Inc. (NASDAQ-ALMR), a research and development company in the diagnostic testing area, today announced it has received clearance from the U.S. Food and Drug Administration for its semi-automated reading instrument (READar(TM)) to interpret results for the gram positive antibiotic MIC susceptibility kit. In July, the instrument was cleared for use with Alamar's gram negative kit, making the READar(TM) useable with two of the company's three test kits.
 Kenneth D. Miller, chief executive officer of Alamar, said, "This clearance enhances the marketability of the READar(TM) instrument in that it is useable with two of our key diagnostic test kits. The FDA is still evaluating our bacterial identification kit as well as the READar(TM) for use with that kit. Upon obtaining those two clearances, we will have completed our initial major product line."
 Miller said the READar(TM) and Alamar's test kits are available worldwide through a network of international distributors and the company's domestic sales force. Sales targets for the products include laboratories, research hospitals and other health care providers. "Approximately 25 percent of the U.S. market uses semi-automated reading instruments representing over $60 million annually," Miller said. "Our instrument can provide an accurate and reproducible test result in approximately 20 seconds and is priced competitively with other readers."
 Currently, Alamar has two remaining applications pending before the FDA, which relate to the company's manual bacterial identification test kit and using the READar(TM) semi-automated instrument with the ID kit. Once cleared, these products will complete Alamar's initial product portfolio for the manual and semi-automated products that are capable of collectively addressing approximately two-thirds of an estimated $530 million worldwide market.
 Common stock in Alamar Biosciences Inc. is traded on NASDAQ under the symbol ALMR. The company develops, manufactures and markets in vitro (outside the body) testing products for hospitals, reference laboratories and other health care providers. Alamar markets alamar Blue(TM), an indicator dye for determining cell viability in research and biotechnology applications.
 For more information on Alamar Biosciences Inc. by FAX, dial 1-800-PRO-INFO, extension 141.
 -0- 9/14/93
 /CONTACT: Kenneth Miller of Alamar Biosciences Inc., 916/567-3475; or Elizabeth Truax of Financial Relations Board, 415-986-1591, for Alamar Biosciences/


CO: Alamar Biosciences Inc. ST: California IN: MTC SU:

PK -- SF007 -- 1608 09/14/93 09:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 14, 1993
Words:391
Previous Article:EXPANDING THE PACIFIC BASIN MARKETPLACE: APL OFFERS COMMERCIAL CONTAINER SERVICE TO/FROM RUSSIAN FAR EAST
Next Article:SYNTEX LABS SIGNS UP FOR NATIONAL ROLL-OUT OF NEW PATIENT COMPLIANCE SYSTEM FROM GENERAL COMPUTER/ZADOX JOINT VENTURE
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters